☰

Paula M. Cannon - Publications

Affiliations: 
Biochemistry and Molecular Biology: Doctor of Philosophy University of Southern California, Los Angeles, CA, United States 
Area:
Molecular Biology
Tree Info Grants Similar researchers PubMed Report error

81 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Llewellyn GN, Chen HY, Rogers GL, Huang X, Sell PJ, Henley JE, Cannon PM. Comparison of SARS-CoV-2 entry inhibitors based on ACE2 receptor or engineered Spike-binding peptides. Journal of Virology. 97: e0068423. PMID 37555663 DOI: 10.1128/jvi.00684-23  0.307
2021 Deeks SG, Archin N, Cannon P, Collins S, Jones RB, de Jong MAWP, Lambotte O, Lamplough R, Ndung'u T, Sugarman J, Tiemessen CT, Vandekerckhove L, Lewin SR. Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021. Nature Medicine. PMID 34848888 DOI: 10.1038/s41591-021-01590-5  0.393
2021 Chen HY, Huang C, Tian L, Huang X, Zhang C, Llewellyn GN, Rogers GL, Andresen K, O'Gorman MRG, Chen YW, Cannon PM. Cytoplasmic tail truncation of SARS-CoV-2 Spike protein enhances titer of pseudotyped vectors but masks the effect of the D614G mutation. Journal of Virology. JVI0096621. PMID 34495700 DOI: 10.1128/JVI.00966-21  0.38
2020 Bougioukli S, Chateau M, Morales H, Vakhshori V, Sugiyama O, Oakes D, Longjohn D, Cannon P, Lieberman JR. Limited potential of AAV-mediated gene therapy in transducing human mesenchymal stem cells for bone repair applications. Gene Therapy. PMID 32807899 DOI: 10.1038/S41434-020-0182-4  0.378
2019 Cannon PM. Gene Editing Expands the Donor Pool for CCR5-Negative Stem Cell Transplants. Cell Stem Cell. 25: 735-736. PMID 31809736 DOI: 10.1016/J.Stem.2019.11.006  0.331
2019 Rogers GL, Chen HY, Morales H, Cannon PM. Homologous Recombination-Based Genome Editing by Clade F AAVs Is Inefficient in the Absence of a Targeted DNA Break. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 31540849 DOI: 10.1016/J.Ymthe.2019.08.019  0.39
2019 Llewellyn GN, Seclèn E, Wietgrefe S, Liu S, Chateau M, Pei H, Perkey K, Marsden MD, Hinkley SJ, Paschon DE, Holmes MC, Zack JA, Louie SG, Haase AT, Cannon PM. A humanized mouse model of HIV-1 latency with enrichment of latent virus in PD-1+ and TIGIT+ CD4 T cells. Journal of Virology. PMID 30842333 DOI: 10.1128/Jvi.02086-18  0.491
2019 Voss JE, Gonzalez-Martin A, Andrabi R, Fuller RP, Murrell B, McCoy LE, Porter K, Huang D, Li W, Sok D, Le K, Briney B, Chateau M, Rogers G, Hangartner L, ... ... Cannon P, et al. Reprogramming the antigen specificity of B cells using genome-editing technologies. Elife. 8. PMID 30648968 DOI: 10.7554/Elife.42995  0.417
2017 Llewellyn GN, Alvarez-Carbonell D, Chateau M, Karn J, Cannon PM. HIV-1 infection of microglial cells in a reconstituted humanized mouse model and identification of compounds that selectively reverse HIV latency. Journal of Neurovirology. PMID 29256041 DOI: 10.1007/S13365-017-0604-2  0.467
2017 Canny MD, Moatti N, Wan LCK, Fradet-Turcotte A, Krasner D, Mateos-Gomez PA, Zimmermann M, Orthwein A, Juang YC, Zhang W, Noordermeer SM, Seclen E, Wilson MD, Vorobyov A, Munro M, ... ... Cannon PM, et al. Inhibition of 53BP1 favors homology-dependent DNA repair and increases CRISPR-Cas9 genome-editing efficiency. Nature Biotechnology. PMID 29176614 DOI: 10.1038/Nbt.4021  0.302
2017 Rogers GL, Cannon PM. Gene Therapy Approaches to Human Immunodeficiency Virus and Other Infectious Diseases. Hematology/Oncology Clinics of North America. 31: 883-895. PMID 28895854 DOI: 10.1016/J.Hoc.2017.06.008  0.393
2017 Kalkavan H, Sharma P, Kasper S, Helfrich I, Pandyra AA, Gassa A, Virchow I, Flatz L, Brandenburg T, Namineni S, Heikenwalder M, Höchst B, Knolle PA, Wollmann G, von Laer D, ... ... Cannon PM, et al. Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression. Nature Communications. 8: 14447. PMID 28248314 DOI: 10.1038/Ncomms14447  0.317
2016 DiGiusto DL, Cannon PM, Holmes MC, Li L, Rao A, Wang J, Lee G, Gregory PD, Kim KA, Hayward SB, Meyer K, Exline C, Lopez E, Henley J, Gonzalez N, et al. Preclinical development and qualification of ZFN-mediated CCR5 disruption in human hematopoietic stem/progenitor cells. Molecular Therapy. Methods & Clinical Development. 3: 16067. PMID 27900346 DOI: 10.1038/Mtm.2016.67  0.439
2016 Wang CX, Cannon PM. Clinical Applications of Genome Editing to HIV Cure. Aids Patient Care and Stds. PMID 27854119 DOI: 10.1089/apc.2016.0233  0.342
2016 Lederman MM, Cannon PM, Currier JS, June CH, Kiem HP, Kuritzkes DR, Lewin SR, Margolis DM, McCune JM, Mellors JW, Schacker TW, Sekaly RP, Tebas P, Walker BD, Douek DC. A Cure for HIV Infection: "Not in My Lifetime" or "Just Around the Corner"? Pathogens & Immunity. 1: 154-164. PMID 27668293 DOI: 10.20411/pai.v1i1.133  0.303
2016 Woodham AW, Skeate JG, Sanna AM, Taylor JR, Da Silva DM, Cannon PM, Kast WM. Human Immunodeficiency Virus Immune Cell Receptors, Coreceptors, and Cofactors: Implications for Prevention and Treatment. Aids Patient Care and Stds. 30: 291-306. PMID 27410493 DOI: 10.1089/apc.2016.0100  0.39
2016 Deeks SG, Lewin SR, Ross AL, Ananworanich J, Benkirane M, Cannon P, Chomont N, Douek D, Lifson JD, Lo YR, Kuritzkes D, Margolis D, Mellors J, Persaud D, Tucker JD, et al. International AIDS Society global scientific strategy: towards an HIV cure 2016. Nature Medicine. PMID 27400264 DOI: 10.1038/Nm.4108  0.406
2016 Wang CX, Cannon PM. The clinical applications of genome editing in HIV. Blood. PMID 27053530 DOI: 10.1182/Blood-2016-01-678144  0.423
2016 Stan R, DiGiusto D, Cannon P, Exline C, Li L, Rao A, Wang J, Lee G, Gregory PD, Gonzalez N, Bedell V, Holmes MC, Zaia JA. 734. Pre-Clinical Development and Qualification of ZFN-Mediated Disruption of CCR5 in Human Hematopoietic Stem and Progenitor Cells Molecular Therapy. 24: S289-S290. DOI: 10.1016/S1525-0016(16)33542-0  0.448
2016 Seclen E, Chen H, Llewellyn GN, Yang SJ, Chateau M, Wang CX, Cannon PM. 330. Using CRISPR/Cas9 to Edit Hematopoietic Stem and Progenitor Cells Molecular Therapy. 24. DOI: 10.1016/S1525-0016(16)33139-2  0.402
2015 Wang J, Exline CM, DeClercq JJ, Llewellyn GN, Hayward SB, Li PW, Shivak DA, Surosky RT, Gregory PD, Holmes MC, Cannon PM. Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nature Biotechnology. PMID 26551060 DOI: 10.1038/Nbt.3408  0.329
2015 Exline CM, Yang SJ, Haworth KG, Rengarajan S, Lopez LA, Droniou ME, Seclen E, Cannon PM. Determinants in HIV-2 Env and tetherin required for functional interaction. Retrovirology. 12: 67. PMID 26248668 DOI: 10.1186/S12977-015-0194-0  0.528
2015 Rathbun JY, Droniou ME, Damoiseaux R, Haworth KG, Henley JE, Exline CM, Choe H, Cannon PM. Novel arenavirus entry inhibitors discovered using a minigenome rescue system for high-throughput drug screening. Journal of Virology. PMID 26041296 DOI: 10.1128/Jvi.00997-15  0.328
2015 Gardner MR, Kattenhorn LM, Kondur HR, von Schaewen M, Dorfman T, Chiang JJ, Haworth KG, Decker JM, Alpert MD, Bailey CC, Neale ES, Fellinger CH, Joshi VR, Fuchs SP, Martinez-Navio JM, ... ... Cannon PM, et al. AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature. 519: 87-91. PMID 25707797 DOI: 10.1038/Nature14264  0.478
2015 Wang J, Exline CM, DeClercq J, Li P, Gregory PD, Cannon PM, Holmes MC. 478. Highly Efficient Targeted Gene Addition in CD34+ Hematopoietic Stem/Progenitor Cells by Combining ZFN mRNA and AAV6 Donor Delivery Molecular Therapy. 23: S190. DOI: 10.1016/S1525-0016(16)34087-4  0.357
2014 Cannon PM, Kohn DB, Kiem HP. HIV eradication--from Berlin to Boston. Nature Biotechnology. 32: 315-6. PMID 24714473 DOI: 10.1038/Nbt.2868  0.413
2013 Hofer U, Henley JE, Exline CM, Mulhern O, Lopez E, Cannon PM. Pre-clinical modeling of CCR5 knockout in human hematopoietic stem cells by zinc finger nucleases using humanized mice. The Journal of Infectious Diseases. 208: S160-4. PMID 24151324 DOI: 10.1093/Infdis/Jit382  0.468
2013 Li L, Krymskaya L, Wang J, Henley J, Rao A, Cao LF, Tran CA, Torres-Coronado M, Gardner A, Gonzalez N, Kim K, Liu PQ, Hofer U, Lopez E, Gregory PD, ... ... Cannon PM, et al. Genomic editing of the HIV-1 coreceptor CCR5 in adult hematopoietic stem and progenitor cells using zinc finger nucleases. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 1259-69. PMID 23587921 DOI: 10.1038/Mt.2013.65  0.489
2013 Lee GK, Truong L, Wood T, Henley J, Ya-Li L, Kim K, Zhou Y, Wang J, Reik A, Urnov FD, Cannon P, Holmes MC, Ando D, Giedlin MA. Autologous Hematopoietic Stem/Progenitor Cell (HSPC) Therapy For Monogenic Blood Disorders: Scalable, cGMP-Compliant Process For Generating Highly Efficient Genome Edited HSPC Blood. 122: 4213-4213. DOI: 10.1182/Blood.V122.21.4213.4213  0.334
2012 Droniou-Bonzom ME, Cannon PM. A systems biology starter kit for arenaviruses. Viruses. 4: 3625-46. PMID 23342371 DOI: 10.3390/V4123625  0.372
2012 Lopez LA, Yang SJ, Exline CM, Rengarajan S, Haworth KG, Cannon PM. Anti-tetherin activities of HIV-1 Vpu and Ebola virus glycoprotein do not involve removal of tetherin from lipid rafts. Journal of Virology. 86: 5467-80. PMID 22398279 DOI: 10.1128/Jvi.06280-11  0.519
2011 Droniou-Bonzom ME, Reignier T, Oldenburg JE, Cox AU, Exline CM, Rathbun JY, Cannon PM. Substitutions in the glycoprotein (GP) of the Candid#1 vaccine strain of Junin virus increase dependence on human transferrin receptor 1 for entry and destabilize the metastable conformation of GP. Journal of Virology. 85: 13457-62. PMID 21976641 DOI: 10.1128/Jvi.05616-11  0.366
2011 Yang SJ, Lopez LA, Exline CM, Haworth KG, Cannon PM. Lack of adaptation to human tetherin in HIV-1 group O and P. Retrovirology. 8: 78. PMID 21955466 DOI: 10.1186/1742-4690-8-78  0.373
2011 Cannon P, June C. Chemokine receptor 5 knockout strategies Current Opinion in Hiv and Aids. 6: 74-79. PMID 21242897 DOI: 10.1097/Coh.0B013E32834122D7  0.447
2011 Hauser H, Lopez LA, Yang SJ, Oldenburg JE, Exline CM, Guatelli JC, Cannon PM. Correction: HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment Retrovirology. 85. DOI: 10.1186/1742-4690-8-85  0.373
2010 Holt N, Wang J, Kim K, Friedman G, Wang X, Taupin V, Crooks GM, Kohn DB, Gregory PD, Holmes MC, Cannon PM. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nature Biotechnology. 28: 839-47. PMID 20601939 DOI: 10.1038/Nbt.1663  0.446
2010 Hauser H, Lopez LA, Yang SJ, Oldenburg JE, Exline CM, Guatelli JC, Cannon PM. HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment. Retrovirology. 7: 51. PMID 20529266 DOI: 10.1186/1742-4690-7-51  0.508
2010 Lopez LA, Yang SJ, Hauser H, Exline CM, Haworth KG, Oldenburg J, Cannon PM. Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal. Journal of Virology. 84: 7243-55. PMID 20444895 DOI: 10.1128/Jvi.02636-09  0.568
2010 Yang SJ, Lopez LA, Hauser H, Exline CM, Haworth KG, Cannon PM. Anti-tetherin activities in Vpu-expressing primate lentiviruses. Retrovirology. 7: 13. PMID 20167081 DOI: 10.1186/1742-4690-7-13  0.532
2010 Christodoulopoulos I, Droniou-Bonzom ME, Oldenburg JE, Cannon PM. Vpu-dependent block to incorporation of GaLV Env into lentiviral vectors. Retrovirology. 7: 4. PMID 20102634 DOI: 10.1186/1742-4690-7-4  0.691
2010 Lucas TM, Lyddon TD, Cannon PM, Johnson MC. Pseudotyping incompatibility between HIV-1 and gibbon ape leukemia virus Env is modulated by Vpu. Journal of Virology. 84: 2666-74. PMID 20042505 DOI: 10.1128/Jvi.01562-09  0.555
2010 Martin VK, Droniou-Bonzom ME, Reignier T, Oldenburg JE, Cox AU, Cannon PM. Investigation of clade B New World arenavirus tropism by using chimeric GP1 proteins. Journal of Virology. 84: 1176-82. PMID 19889757 DOI: 10.1128/Jvi.01625-09  0.446
2009 Sumiyoshi T, Holt NG, Hollis RP, Ge S, Cannon PM, Crooks GM, Kohn DB. Stable transgene expression in primitive human CD34+ hematopoietic stem/progenitor cells, using the Sleeping Beauty transposon system. Human Gene Therapy. 20: 1607-26. PMID 19689196 DOI: 10.1089/Hum.2009.109  0.365
2008 Kahl CA, Cannon PM, Oldenburg J, Tarantal AF, Kohn DB. Tissue-specific restriction of cyclophilin A-independent HIV-1- and SIV-derived lentiviral vectors. Gene Therapy. 15: 1079-89. PMID 18385767 DOI: 10.1038/Gt.2008.50  0.55
2008 Flanagan ML, Oldenburg J, Reignier T, Holt N, Hamilton GA, Martin VK, Cannon PM. New world clade B arenaviruses can use transferrin receptor 1 (TfR1)-dependent and -independent entry pathways, and glycoproteins from human pathogenic strains are associated with the use of TfR1. Journal of Virology. 82: 938-48. PMID 18003730 DOI: 10.1128/Jvi.01397-07  0.372
2008 Reignier T, Oldenburg J, Flanagan ML, Hamilton GA, Martin VK, Cannon PM. Receptor use by the Whitewater Arroyo virus glycoprotein. Virology. 371: 439-46. PMID 17997467 DOI: 10.1016/J.Virol.2007.10.004  0.427
2007 Weber EL, Cannon PM. Promoter choice for retroviral vectors: transcriptional strength versus trans-activation potential. Human Gene Therapy. 18: 849-60. PMID 17767401 DOI: 10.1089/Hum.2007.067  0.374
2007 Oldenburg J, Reignier T, Flanagan ML, Hamilton GA, Cannon PM. Differences in tropism and pH dependence for glycoproteins from the Clade B1 arenaviruses: implications for receptor usage and pathogenicity. Virology. 364: 132-9. PMID 17397892 DOI: 10.1016/J.Virol.2007.03.003  0.412
2006 Reignier T, Oldenburg J, Noble B, Lamb E, Romanowski V, Buchmeier MJ, Cannon PM. Receptor use by pathogenic arenaviruses. Virology. 353: 111-20. PMID 16797051 DOI: 10.1016/J.Virol.2006.05.018  0.383
2006 Noble B, Abada P, Nunez-Iglesias J, Cannon PM. Recruitment of the adaptor protein 2 complex by the human immunodeficiency virus type 2 envelope protein is necessary for high levels of virus release. Journal of Virology. 80: 2924-32. PMID 16501101 DOI: 10.1128/Jvi.80.6.2924-2932.2006  0.757
2006 Weber EL, Cannon PM. 828. Promoter Strength Versus Transactivation Potential: Creating a Safer Integrating Vector Molecular Therapy. 13. DOI: 10.1016/J.Ymthe.2006.08.913  0.367
2006 Kahl CA, Cannon PM, Oldenburg J, Kohn DB. 368. Lentiviral Vector Strain of Origin and Target Cell Species-Specific Restriction Factors Influence Transduction Efficiency Molecular Therapy. 13: S140. DOI: 10.1016/J.Ymthe.2006.08.427  0.522
2005 Abada P, Noble B, Cannon PM. Functional domains within the human immunodeficiency virus type 2 envelope protein required to enhance virus production. Journal of Virology. 79: 3627-38. PMID 15731257 DOI: 10.1128/Jvi.79.6.3627-3638.2005  0.761
2004 Kobayashi H, Petersen D, Carbonaro D, Skelton D, Ge S, Luzko C, Cannon P, Dussel MO, Rosol M, Moats R, Shimada H, Kohn DB. 696. Comparative study of lentiviral vector-mediated gene therapy in neonatal and young-adult MPS I mice by a single intravenous injection Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.647  0.306
2004 Oldenburg J, Logan AC, Barcova M, Ngiam C, Cannon PM. 68. Improved lentiviral vector system with enhanced safety features Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.003  0.45
2003 Aguilar HC, Anderson WF, Cannon PM. Cytoplasmic tail of Moloney murine leukemia virus envelope protein influences the conformation of the extracellular domain: implications for mechanism of action of the R Peptide. Journal of Virology. 77: 1281-91. PMID 12502845 DOI: 10.1128/Jvi.77.2.1281-1291.2003  0.487
2002 Chen M, Kasahara N, Keene DR, Chan L, Hoeffler WK, Finlay D, Barcova M, Cannon PM, Mazurek C, Woodley DT. Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa. Nature Genetics. 32: 670-5. PMID 12426566 DOI: 10.1038/Ng1041  0.316
2002 Lin AH, Cannon PM. Use of pseudotyped retroviral vectors to analyze the receptor-binding pocket of hemagglutinin from a pathogenic avian influenza A virus (H7 subtype). Virus Research. 83: 43-56. PMID 11864740 DOI: 10.1016/S0168-1702(01)00407-5  0.456
2001 Borok Z, Harboe-Schmidt JE, Brody SL, You Y, Zhou B, Li X, Cannon PM, Kim KJ, Crandall ED, Kasahara N. Vesicular stomatitis virus G-pseudotyped lentivirus vectors mediate efficient apical transduction of polarized quiescent primary alveolar epithelial cells. Journal of Virology. 75: 11747-54. PMID 11689655 DOI: 10.1128/Jvi.75.23.11747-11754.2001  0.462
2001 Masood R, Gordon EM, Whitley MD, Wu BW, Cannon P, Evans L, Anderson WF, Gill P, Hall FL. Retroviral vectors bearing IgG-binding motifs for antibody-mediated targeting of vascular endothelial growth factor receptors. International Journal of Molecular Medicine. 8: 335-43. PMID 11562769 DOI: 10.3892/Ijmm.8.4.335  0.439
2001 Logg CR, Logg A, Tai CK, Cannon PM, Kasahara N. Genomic stability of murine leukemia viruses containing insertions at the Env-3' untranslated region boundary. Journal of Virology. 75: 6989-98. PMID 11435579 DOI: 10.1128/Jvi.75.15.6989-6998.2001  0.43
2001 Christodoulopoulos I, Cannon PM. Sequences in the cytoplasmic tail of the gibbon ape leukemia virus envelope protein that prevent its incorporation into lentivirus vectors. Journal of Virology. 75: 4129-38. PMID 11287562 DOI: 10.1128/Jvi.75.9.4129-4138.2001  0.68
2001 Lin AH, Kasahara N, Wu W, Stripecke R, Empig CL, Anderson WF, Cannon PM. Receptor-specific targeting mediated by the coexpression of a targeted murine leukemia virus envelope protein and a binding-defective influenza hemagglutinin protein Human Gene Therapy. 12: 323-332. PMID 11242525 DOI: 10.1089/10430340150503957  0.504
2000 Wu BW, Lu J, Gallaher TK, Anderson WF, Cannon PM. Identification of regions in the Moloney murine leukemia virus SU protein that tolerate the insertion of an integrin-binding peptide. Virology. 269: 7-17. PMID 10725193 DOI: 10.1006/Viro.2000.0201  0.433
1999 Benedict CA, Tun RY, Rubinstein DB, Guillaume T, Cannon PM, Anderson WF. Targeting retroviral vectors to CD34-expressing cells: binding to CD34 does not catalyze virus-cell fusion. Human Gene Therapy. 10: 545-57. PMID 10094198 DOI: 10.1089/10430349950018625  0.399
1998 Han J, Zhao Y, Anderson WF, Cannon PM. Role of Variable Regions A and B in Receptor Binding Domain of Amphotropic Murine Leukemia Virus Envelope Protein Journal of Virology. 72: 9101-9108. PMID 9765455 DOI: 10.1128/Jvi.72.11.9101-9108.1998  0.414
1998 Zhao Y, Zhu L, Benedict CA, Chen D, Anderson WF, Cannon PM. Functional domains in the retroviral transmembrane protein. Journal of Virology. 72: 5392-5398. PMID 9620993 DOI: 10.1128/Jvi.72.7.5392-5398.1998  0.585
1998 Weimin Wu B, Cannon PM, Gordon EM, Hall FL, Anderson WF. Characterization of the proline-rich region of murine leukemia virus envelope protein. Journal of Virology. 72: 5383-91. PMID 9620992 DOI: 10.1128/Jvi.72.7.5383-5391.1998  0.526
1998 Zhu NL, Cannon PM, Chen D, Anderson WF. Mutational analysis of the fusion peptide of Moloney murine leukemia virus transmembrane protein p15E. Journal of Virology. 72: 1632-9. PMID 9445069 DOI: 10.1128/Jvi.72.2.1632-1639.1998  0.512
1997 Han JY, Cannon PM, Lai KM, Zhao Y, Eiden MV, Anderson WF. Identification of envelope protein residues required for the expanded host range of 10A1 murine leukemia virus. Journal of Virology. 71: 8103-8108. PMID 9343159 DOI: 10.1128/Jvi.71.11.8103-8108.1997  0.381
1997 Januszeski MM, Cannon PM, Chen D, Rozenberg Y, Anderson WF. Functional analysis of the cytoplasmic tail of Moloney murine leukemia virus envelope protein. Journal of Virology. 71: 3613-3619. PMID 9094634 DOI: 10.1128/Jvi.71.5.3613-3619.1997  0.51
1997 Cannon PM, Matthews S, Clark N, Byles ED, Iourin O, Hockley DJ, Kingsman SM, Kingsman AJ. Structure-function studies of the human immunodeficiency virus type 1 matrix protein, p17. Journal of Virology. 71: 3474-3483. PMID 9094619 DOI: 10.1128/Jvi.71.5.3474-3483.1997  0.516
1996 Cannon PM, Kim N, Kingsman SM, Kingsman AJ. Murine leukemia virus-based Tat-inducible long terminal repeat replacement vectors: a new system for anti-human immunodeficiency virus gene therapy. Journal of Virology. 70: 8234-8240. PMID 8892960 DOI: 10.1128/Jvi.70.11.8234-8240.1996  0.537
1996 Cannon PM, Byles ED, Kingsman SM, Kingsman AJ. Conserved sequences in the carboxyl terminus of integrase that are essential for human immunodeficiency virus type 1 replication. Journal of Virology. 70: 651-657. PMID 8523588 DOI: 10.1128/Jvi.70.1.651-657.1996  0.533
1995 Soneoka Y, Cannon PM, Ramsdale EE, Griffiths JC, Romano G, Kingsman SM, Kingsman AJ. A transient three-plasmid expression system for the production of high titer retroviral vectors Nucleic Acids Research. 23: 628-633. PMID 7899083 DOI: 10.1093/Nar/23.4.628  0.424
1994 Braddock M, Cannon P, Muckenthaler M, Kingsman AJ, Kingsman SM. Inhibition of human immunodeficiency virus type 1 Tat-dependent activation of translation in Xenopus oocytes by the benzodiazepine Ro24-7429 requires trans-activation response element loop sequences. Journal of Virology. 68: 25-33. PMID 8254735 DOI: 10.1128/Jvi.68.1.25-33.1994  0.429
1994 Cannon P, Kim S, Ulich C, Kim S. Analysis of Tat function in human immunodeficiency virus type 1-infected low-level-expression cell lines U1 and ACH-2. Journal of Virology. 68: 1993-1997. PMID 8107261 DOI: 10.1128/Jvi.68.3.1993-1997.1994  0.519
1994 Cannon PM, Wilson W, Byles E, Kingsman SM, Kingsman AJ. Human immunodeficiency virus type 1 integrase: effect on viral replication of mutations at highly conserved residues. Journal of Virology. 68: 4768-4775. PMID 8035478 DOI: 10.1128/Jvi.68.8.4768-4775.1994  0.475
1993 Cannon P, Tenen D, Feinberg M, Shin H, Kim S. Human immunodeficiency virus-1 infection of the human promyelocytic cell line HL-60: high frequency of low-level infection and effect of subsequent cell differentiation Blood. 81: 437-445. DOI: 10.1182/blood.v81.2.437.bloodjournal812437  0.354
1993 Cannon PM, Tenen DG, Feinberg MB, Shin HS, Kim S. Human immunodeficiency virus-1 infection of the human promyelocytic cell line HL-60 : high frequency of low-level infection and effect of subsequent cell differentiation Blood. 81: 437-445. DOI: 10.1182/Blood.V81.2.437.437  0.455
1992 Luo L, Li Y, Cannon PM, Kim S, Kang CY. Chimeric gag-V3 virus-like particles of human immunodeficiency virus induce virus-neutralizing antibodies. Proceedings of the National Academy of Sciences of the United States of America. 89: 10527-31. PMID 1438241 DOI: 10.1073/Pnas.89.21.10527  0.529
Show low-probability matches.